Performance of two Real-Time RT-PCR assays for quantitation of hepatitis C virus RNA: Evaluation on HCV genotypes 1-4

Journal of Medical Virology

Volumn 82, Issue 11, 2010, Pages 1878-1888

  Elkady, Abeer ^a   Tanaka, Yasuhito ^a   Kurbanov, Fuat ^a   Sugauchi, Fuminaka ^a   Sugiyama, Masaya ^a   Khan, Anis ^a   Ali, Elsayed Mostafa ^b   Mouhamed, Layla ^b   Abou el fetouh, Sahar ^b   Abdel Hameed, Abdel Rahaman ^c   Mizokami, Masashi ^d  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Sohag University   (Egypt)

^c South Valley University   (Egypt)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Cobas Ampliprep Cobas TaqMan; Genotype 4; HCV core antigen; Hepatitis C virus; Real time PCR

Indexed keywords

CORE PROTEIN; HEPATITIS C ANTIGEN; VIRUS RNA;

5' UNTRANSLATED REGION; ARTICLE; BLOOD; CLASSIFICATION; DNA SEQUENCE; EVALUATION; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; ISOLATION AND PURIFICATION; LUMINESCENCE; METHODOLOGY; MOLECULAR GENETICS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARD; VIROLOGY; VIRUS GENOME;

5' UNTRANSLATED REGIONS; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOASSAY; LUMINESCENCE; MOLECULAR SEQUENCE DATA; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; VIRAL CORE PROTEINS;

EID: 79952117233     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21911     Document Type: Article

References (42)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. 1989. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494-1500.
2. Alvarez M, Planelles D, Vila E, Montoro J, Franco E. 2004. Prolonged hepatitis C virus seroconversion in a blood donor, detected by HCV antigen test in parallel with HCV RNA. Vox Sang 86: 266-267.
3. Beld M, Sentjens R, Rebers S, Weegink C, Weel J, Sol C, Boom R. 2002. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: Conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 40: 788-793.
4. Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310.
5. Caliendo AM, Valsamakis A, Zhou Y, Yen-Lieberman B, Andersen J, Young S, Ferreira-Gonzalez A, Tsongalis GJ, Pyles R, Bremer JW, Lurain NS. 2006. Multilaboratory comparison of hepatitis C virus viral load assays. J Clin Microbiol 44: 1726-1732.
6. Cantaloube JF, Gallian P, Attoui H, Biagini P, De Micco P, de Lamballerie X. 2005. Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France. J Clin Microbiol 43: 3624-3629.
7. Chevaliez S, Pawlotsky JM. 2005. Use of virologic assays in the diagnosis and management of hepatitis C virus infection. Clin Liver Dis 9: 371-382.
8. Chevaliez S, Pawlotsky JM. 2007. Practical use of hepatitis C virus kinetics monitoring in the treatment of chronic hepatitis C. J Viral Hepat 14: 77-81.
9. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. 2007. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46: 22-31.
10. Chevaliez S, Bouvier-Alias M, Castera L, Pawlotsky JM. 2009a. The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples. Hepatology 49: 1397-1398.
11. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. 2009b. Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J Clin Microbiol 47: 1726-1732.
12. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339: 1493-1499.
13. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Chaneac M, Reddy KR. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433.
14. Genovese D, Dettori S, Argentini C, Villano U, Chionne P, Angelico M, Rapicetta M. 2005. Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol 43: 1902-1909.
15. Hino K, Kitase A, Satoh Y, Fujiwara D, Yamaguchi Y, Korenaga M, Shingai Y, Konishi T, Yamashita S, Uchida K, Mori K, Hanada H, Kodama T, Nukui K, Okita K. 2002. Interferon retreatment reduces or delays the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. J Viral Hepat 9: 370-376.
16. Hnatyszyn HJ. 2005. Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes. Antivir Ther 10: 1-11.
17. Kanwal F, Hoang T, Spiegel BM, Eisen S, Dominitz JA, Gifford A, Goetz M, Asch SM. 2007. Predictors of treatment in patients with chronic hepatitis C infection-Role of patient versus nonpatient factors. Hepatology 46: 1741-1749.
18. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter HJ. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675.
19. Lee SS, Abdo AA. 2003. Predicting antiviral treatment response in chronic hepatitis C: How accurate and how soon? J Antimicrob Chemother 51: 487-491.
20. Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. 2007. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV-RNA at day 0, day 22, day 29, and week 6. Hepatology 45: 258-259.
21. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A. 2009. Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology 49: 358-363.
22. McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, Schmid P, Conrad A. 1998a. Is there an optimal time to measure quantitative HCV RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 29: 362-368.
23. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998b. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492.
24. Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P. 1995. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: Implications for virus classification. The International HCV Collaborative Study Group. J Gen Virol 76: 2493-2507.
25. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. 2009. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 157: 8-14.
26. Nicot F, Legrand-Abravanel F, Sandres-Saune K, Boulestin A, Dubois M, Alric L, Vinel JP, Pasquier C, Izopet J. 2005. Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol 86: 107-114.
27. Orito E, Mizokami M, Tanaka T, Lau JY, Suzuki K, Yamauchi M, Ohta Y, Hasegawa A, Tanaka S, Kohara M. 1996. Quantification of serum hepatitis C virus core protein level in patients chronically infected with different hepatitis C virus genotypes. Gut 39: 876-880.
28. Pawlotsky JM, Martinot-Peignoux M, Poveda JD, Bastie A, Le Breton V, Darthuy F, Remire J, Erlinger S, Dhumeaux D, Marcellin P. 1999. Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays. J Virol Methods 79: 227-235.
29. Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, Colucci G, Smedile A, Ghisetti V. 2008. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol 80: 254-260.
30. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182: 698-707.
31. Saldanha J, Heath A, Aberham C, Albrecht J, Gentili G, Gessner M, Pisani G. 2005a. World Health Organization collaborative study to establish a replacement WHO International Standard for hepatitis C virus RNA nucleic acid amplification technology assays. Vox Sang 88: 202-204.
32. Saldanha J, Heath A, Lelie N, Pisani G, Yu MY. 2005b. A World Health Organization International Standard for hepatitis A virus RNA nucleic acid amplification technology assays. Vox Sang 89: 52-58.
33. Sarrazin C, Dragan A, Gartner BC, Forman MS, Traver S, Zeuzem S, Valsamakis A. 2008. Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. J Clin Virol 43: 162-168.
34. Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. 1997. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 113: 558-566.
35. Simmonds P, Mellor J, Sakuldamrongpanich T, Nuchaprayoon C, Tanprasert S, Holmes EC, Smith DB. 1996. Evolutionary analysis of variants of hepatitis C virus found in South-East Asia: Comparison with classifications based upon sequence similarity. J Gen Virol 77: 3013-3024.
36. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
37. Smith DB, Pathirana S, Davidson F, Lawlor E, Power J, Yap PL, Simmonds P. 1997. The origin of hepatitis C virus genotypes. J Gen Virol 78: 321-328.
38. Tanaka Y, Hanada K, Mizokami M, Yeo AE, Shih JW, Gojobori T, Alter HJ. 2002. Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci USA 99: 15584-15589.
39. Tanaka Y, Takagi K, Fujihara T, Kitsugi K, Fujiwara K, Hiramatsu K, Ito Y, Takasaka Y, Sakai M, Mizokami M. 2003. High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol Res 26: 261-267.
40. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. 2008. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 46: 3880-3891.
41. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. 2006. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther 11: 985-994.
42. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C, Albrecht J. 2006. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 44: 97-103.